Goldman Sachs
RLMD icon

Goldman Sachs’s Relmada Therapeutics RLMD Stock Holding History

Goldman Sachs’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,300
Closed -$169K – 6928
2026
Q1 		$169K Hold
24,300
– – ﹤0.01% 6127
2025
Q4 		$117K Buy
+24,300
New +$81.4K ﹤0.01% 6165
2021
Q3 		– Sell
-12,600
Closed -$403K – 6468
2021
Q2 		$403K Hold
12,600
– – ﹤0.01% 5341
2021
Q1 		$444K Buy
+12,600
New +$441K ﹤0.01% 5207

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's RLMD Position: Q2 2026 in Review

Goldman Sachs increased its Relmada Therapeutics (RLMD) stake by 9.8% in Q2 2026, buying an estimated $479K and bringing the position to 767,624 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3832.

Goldman Sachs first reported a position in RLMD in Q4 2019 and has held it in 19 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Goldman Sachs held 767,624 shares of Relmada Therapeutics worth $5.31M as of Q2 2026.
  • Goldman Sachs bought 68,585 Relmada Therapeutics shares in Q2 2026, an estimated $479K.
  • Relmada Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3832 holding.
  • Goldman Sachs first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.